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Associations of obstructive sleep 
apnea with truncal skeletal muscle 
mass and density
Takeshi Matsumoto1, Kiminobu Tanizawa2, Ryo Tachikawa1, Kimihiko Murase1, Takuma Minami1, 
Morito Inouchi2, Tomohiro Handa1, Toru Oga2, Toyohiro Hirai1 & Kazuo Chin2
Sarcopenia has been associated with several conditions relevant to obstructive sleep apnea (OSA), 
such as aging and obesity, but a direct relationship between OSA and skeletal muscle alterations 
has not been identified. This study investigated associations between computed tomography (CT)-
measured skeletal muscle indices and OSA severity. Analyzed were 334 patients who underwent 
polysomnography to diagnose OSA. Lumbar skeletal muscles were assessed with CT for the skeletal 
muscle mass index (SMI, cross-sectional area, normalized for height squared) and skeletal muscle 
density (SMD, fat infiltration). The apnea-hypopnea index (AHI) correlated positively with the SMI and 
negatively with SMD in both men and women. The AHI was weakly associated with SMI only in men 
(β = 0.11, P = 0.017) after adjustment for the body mass index (BMI) (BMI: β = 0.61, P < 0.001 in men, 
β = 0.65, P < 0.001 in women). The association of AHI and SMD was not significant after adjustment for 
BMI (BMI: β = −0.42, P < 0.001 in men, β = −0.64, P < 0.001 in women). Severity of OSA correlated 
with increases in skeletal muscle mass rather than muscle depletion and skeletal muscle adiposity. 
These associations were limited compared with the stronger associations between obesity and skeletal 
muscles.
Sarcopenia is the loss of systemic skeletal muscle mass accompanied by decreased strength and function1. 
Sarcopenia has been of increasing interest because skeletal muscle depletion has been observed in several condi-
tions such as aging, chronic obstructive pulmonary disease (COPD), metabolic syndrome, and cancer2–6. In fact, 
decreased skeletal muscle mass assessed by computed tomography (CT) and other measures was a significant 
predictor of overall survival of patients with cancer and COPD4,7,8. These findings suggest that skeletal muscle 
changes can reflect the systemic effects and burdens of chronic diseases. In addition, low skeletal muscle density 
(SMD) values on CT indicated fat infiltration into muscles and was associated with muscle dysfunction, aging, 
and obesity2,3,9,10. Thus, these CT measurements (mass volume and density) can be useful for assessment of differ-
ent changes in skeletal muscles (depletion and fat accumulation) and could be associated with various conditions 
and their consequences.
Obstructive sleep apnea (OSA) is a common sleep disordered breathing condition. OSA has significant effects 
on various organ systems such as the cardiovascular (hypertension; ischemic heart disease), endocrinal (glucose 
intolerance; dyslipidemia), and central and sympathetic nervous systems (cognitive impairment; sympathetic 
activation)11. Among these comorbidities associated with OSA, hypertension, and diabetes are also associated 
with sarcopenia12. Given the wide range of the systemic impact of OSA, OSA can also profoundly affect skele-
tal muscles in the whole body. In addition, OSA was associated with ageing and obesity13, both of which were 
reported to be accompanied by skeletal muscle depletion and fat accumulation on CT measurements2,3. These 
findings suggest a possible association between OSA and skeletal muscles in the entire body. However, the direct 
relationship between OSA and skeletal muscle indices has not been investigated with the exception of one study 
that used the bioimpedance method14.
Thus, in this study, we aimed to investigate the relationship between OSA severity and skeletal muscle mass 
and density. We hypothesized that more severe OSA should be associated with greater losses of total skeletal 
muscle mass and increases in fat accumulation in muscles. CT and magnetic resonance imaging (MRI) are gold 
standards for estimating skeletal muscle mass3, and CT measurements at the lumbar level have been used as 
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a surrogate marker for whole body skeletal muscle volume7,15,16. Therefore, using abdominal CT images taken 
to evaluate visceral fat accumulation and to diagnose visceral fat obesity, we assessed lumbar skeletal muscles 
quantitatively in patients suspected to have OSA as the representatives of total skeletal muscles. We then analyzed 
the associations among CT indices of skeletal muscles, OSA parameters, and other confounders such as body 
adiposity and self-reported physical activity.
Results
Baseline characteristics of study patients. During the study period, 740 patients underwent polysom-
nography (PSG), and finally data on 334 patients were analyzed (Fig. 1). Of 334 patients included in the analysis, 
12 (3.6%), 61 (18.3%), 105 (31.4%), and 156 (46.7%) had no (AHI < 5), mild (5 ≤ AHI < 15), moderate (15 ≤ 
AHI < 30), and severe OSA (AHI ≥ 30), respectively. Table 1 shows the baseline characteristics and skeletal 
muscle parameters of study patients according to sex. This comparison revealed that OSA was significantly more 
severe in the men than in the women, and the skeletal muscle mass index (SMI), SMD and subcutaneous fat area 
(SFA) index were significantly higher in the men than in the women (SMI, 52.5 ± 8.4 vs. 42.6 ± 7.5 cm2/m2; SMD, 
35.8 ± 6.5 vs. 30.0 ± 7.8 cm2/m2; SFA index, 47.6 ± 22.1 vs. 76.6 ± 43.5 cm2/m2, all P < 0.001). Neither the BMI nor 
visceral fat area (VFA) index differed between the men and women.
Relationships between SMI and OSA, physical activity, and obesity. Given the significant gen-
der differences in OSA severity and the skeletal muscle parameters, the relationships between skeletal muscle 
parameters and other clinical parameters were analyzed in men and women separately, as reported in previous 
studies4,7,15–19. Correlations between the SMI and clinical variables are shown in Table 2. The SMI was signifi-
cantly correlated with AHI in both men and women (r = 0.35, P < 0.001, and r = 0.24, P = 0.019, respectively) 
(Fig. 2a,b).
Results of the multivariate regression analysis of predictors for the SMI are shown in Table 3. Because there 
was strong collinearity between the BMI and the SFA index in men and women and between the BMI and VFA 
index in women, BMI (Table 3, model 1) and both the VFA index and SFA index (Table 3, model 2) were entered 
into the model separately. After adjusting for age and BMI, the AHI was significantly positively related to SMI in 
men (β = 0.11, P = 0.017), but the BMI was more strongly associated with the SMI in both sexes (Table 3, model 
1). Fat mass was also associated with the SMI (Table 3, model 2). Even when we included the physical activity 
index as a covariate, the results were almost the same (Table 3, model 3). When CT90 or 3%ODI was chosen as 
a parameter of OSA severity instead of the AHI, 3%ODI was significantly positively related to the SMI in men 
(β = 0.12, P = 0.014), but CT90 was not (Supplementary Table S1).
Relationships between SMD and OSA, physical activity, and obesity. Table 2 shows the correla-
tions between SMD and clinical variables. The SMD was significantly correlated with the AHI in both men and 
women (r = −0.15, P = 0.025, and r = −0.29, P = 0.005, respectively) (Fig. 2c,d).
Results of the multivariate regression analysis of predictors for SMD are shown in Table 4. As with the SMI, 
BMI (Table 4, model 1) and both the VFA index and SFA index (Table 4, model 2) were entered into the model 
separately. After adjusting for covariates, the AHI was not related to SMD in either model. However, age, BMI, 
VFA index, and SFA index were independently associated with SMD in both sexes. When CT90 or 3%ODI 
was chosen as a parameter of OSA severity instead of the AHI, neither CT90 nor 3%ODI was related to SMD 
(Supplementary Table S2).
Discussion
To the best of our knowledge, this is the first study to investigate the relationship between OSA severity and skel-
etal muscle mass and density as assessed by CT. In a relatively large cohort of patients suspected to have OSA, the 
AHI significantly and positively correlated with the SMI in both men and women. After adjustment for covariates, 
Figure 1. Flowchart of patient participation. PSG, polysomnography; CT, computed tomography; OSA, 
obstructive sleep apnea.
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the association of the AHI with the SMI remained significant but was much weaker than that of the BMI in men; 
however, the association was not significant for women. The AHI was significantly and negatively correlated with 
SMD in men and women, but this association did not persist in either men or women after adjustment for other 
confounders.
We hypothesized that the severity of OSA negatively correlates with the SMI. However, our results were con-
trary to this hypothesis, showing that OSA was associated with an increased skeletal muscles mass in both men 
and women. Previously, the BMI was reported to be positively correlated with AHI20 and SMI7. Results of our 
multivariate analysis suggested that BMI was the strongest contributor to the SMI in our cohort. On the other 
hand, the independent association of OSA with the SMI was limited although statistically significant after adjust-
ment for the BMI and age. This limited association of OSA with the SMI remained the same even when consider-
ing the effect of daily exercise. Similar results were obtained when VFA and SFA indices for the severity of obesity 
were entered into the analysis instead of the BMI. Taken together our findings suggested that skeletal muscle mass 
is mainly a reflection of body size and the severity of obesity in OSA patients.
The positive correlation between OSA severity and the SMI was contrary to the negative correlation observed 






(n = 95) P value
Age (years) 61.9 ± 10.4 61.8 ± 11.1 62.0 ± 10.6 0.875
BMI (kg/m2) 26.0 ± 4.7 25.9 ± 3.9 26.3 ± 6.4 0.560
AHI (events/h) 31.8 ± 20.0 34.8 ± 19.3 24.2 ± 19.6 <0.001
OSA severity, no/mild/moderate/severe (number, %) 12/61/105/156 (4/18/31/47) 3/33/73/130 (1/14/31/54) 9/28/32/26 (10/30/34/27) <0.001
CT90* (%) 4.6 [0.6–13.4] 6.8 [1.0–15.8] 1.5 [0.2–7.5] <0.001
3%ODI (events/h) 28.8 ± 21.0 31.8 ± 20.7 21.4 ± 20.0 <0.001
Physical activity index*,† (kcal/w) 857 [387–1825] 829 [371–1768] 942 [426–1986] 0.429
Maximum intensity†, no activity/light/moderate/
vigorous (number, %) 29/54/134/44 (11/21/51/17) 21/36/91/36 (11/20/49/20) 8/18/43/8 (10/23/56/10) 0.311
Lumbar skeletal muscle area (cm2) 134.9 ± 33.1 148.4 ± 26.9 100.8 ± 20.0 <0.001
Skeletal muscle mass index (cm2/m2) 49.7 ± 9.3 52.5 ± 8.4 42.6 ± 7.5 <0.001
Skeletal muscle density (HU) 34.1 ± 7.4 35.8 ± 6.5 30.0 ± 7.8 <0.001
Visceral fat area (cm2) 115.7 ± 64.8 121.9 ± 64.0 100.2 ± 64.5 0.006
Visceral fat area index (cm2/m2) 43.0 ± 24.2 43.4 ± 23.1 42.2 ± 27.0 0.707
Subcutaneous fat area (cm2) 148.3 ± 81.5 134.9 ± 64.5 182.1 ± 106.7 <0.001
Subcutaneous fat area index (cm2/m2) 55.9 ± 32.5 47.6 ± 22.1 76.6 ± 43.5 <0.001
Table 1. Patient characteristics and skeletal muscle parameters according to sex. Abbreviations: BMI, body 
mass index; AHI, apnea-hypopnea index; CT90, cumulative percentage of sleep time with SpO2 < 90%; ODI, 
oxygen desaturation index; HU, Hounsfield Unit. Data are expressed as means ± SD, numbers, percentages, or 
medians [interquartile range]. The severity of OSA was defined by AHI levels as follows: no, <5 events/h; mild, 
5-<15 events/h; moderate, 15-<30 events/h; and severe, ≥30 events/h. *Mann-Whitney U test was used, and 
the other continuous variables were calculated by unpaired Student’s t test. †Data were collected for 261 patients 
(184 men, 77 women).
Skeletal muscle mass index Skeletal muscle density
Men Women Men Women
r P value r P value r P value r P value
Age (years) −0.40 <0.001 −0.43 <0.001 −0.43 <0.001 −0.19 0.064
BMI (kg/m2) 0.72 <0.001 0.68 <0.001 −0.27 <0.001 −0.45 <0.001
AHI (events/h) 0.35 <0.001 0.24 0.019 −0.15 0.025 −0.29 0.005
CT90* (%) 0.22 <0.001 0.12 0.233 −0.20 0.002 −0.37 <0.001
3%ODI (events/h) 0.36 <0.001 0.23 0.022 −0.15 0.023 −0.33 0.001
Physical activity index*,† (kcal/w) 0.042 0.574 0.007 0.952 −0.12 0.120 −0.12 0.289
Visceral fat area index (cm2/m2) 0.40 <0.001 0.42 <0.001 −0.35 <0.001 −0.49 <0.001
Subcutaneous fat area index (cm2/m2) 0.50 <0.001 0.56 <0.001 −0.17 0.007 −0.43 <0.001
Table 2. Correlation between skeletal muscle mass index or skeletal muscle density and clinical variables. 
Abbreviations: BMI, body mass index; AHI, apnea-hypopnea index; CT90, cumulative percentage of sleep time 
with SpO2 <90%; ODI, oxygen desaturation index. *Correlations between these variables and skeletal muscle 
mass index or skeletal muscle density were presented by Spearman rank correlation coefficients (ρ), and the 
others were presented by Pearson rank correlation coefficients. †Data were analyzed for 261 patients (184 men, 
77 women).
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Figure 2. Correlation between AHI and the SMI or SMD. (a) Correlation between AHI and SMI in men. (b) 
Correlation between AHI and SMI in women. (c) Correlation between AHI and SMD in men. (d) Correlation 
between AHI and SMD in women. AHI, apnea-hypopnea index; SMI, skeletal muscle mass index; SMD, skeletal 
muscle density.
β P value R2 β P value R2
Model 1 Men (n = 239) Women (n = 95)
AHI (events/h) 0.11 0.017 0.040 — 0.379
Age (years) −0.23 <0.001 0.093 — 0.052
BMI (kg/m2) 0.61 <0.001 0.437 0.65 <0.001 0.438
Cumulative R2 0.570 0.438
Model 2
AHI (events/h) 0.17 0.003 0.061 — 0.759
Age (years) −0.32 <0.001 0.131 −0.28 0.003 0.121
Visceral fat area index (cm2/m2) 0.22 <0.001 0.087 0.204
Subcutaneous fat area index (cm2/m2) 0.24 <0.001 0.118 0.34 0.013 0.190
Cumulative R2 0.397 0.311
Model 3 Men (n = 184) Women (n = 77)
AHI (events/h) 0.14 0.007 0.050 — 0.146
Age (years) −0.16 0.002 0.065 — 0.087
BMI (kg/m2) 0.65 <0.001 0.466 0.72 <0.001 0.490
Physical activity index (kcal/w) — 0.890 — 0.427
Cumulative R2 0.581 0.490
Table 3. Multivariate regression analysis predicting skeletal muscle mass index in men and women. 
Abbreviations: BMI, body mass index; AHI, apnea-hypopnea index; β, standardized regression coefficient; R2, 
coefficient of determination.
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depletion has been associated with the disease burden, probably through cachexia or systemic exhaustion caused 
by the disease. In lung, gastrointestinal, or skin cancer, decreased skeletal muscle mass was associated with 
impaired physical function and poor survival7,21. In chronic heart failure, skeletal muscle depletion has been 
related to reduced exercise capacity and the advancement of the disease22. In COPD, decreased skeletal muscle 
mass was associated with spirometric measurements indicating impaired lung function and poor survival8,23. 
Compared to these exhaustive diseases, OSA may have only a small role in skeletal muscle alterations, and the 
BMI and obesity may have much stronger relationships with the condition of skeletal muscles.
The severity of OSA was negatively correlated with SMD, suggesting that more severe OSA was associated 
with greater fat accumulation in muscles. This finding was consistent with our hypothesis, although the associa-
tion was not independent from obesity. Obesity was shown to be a major confounder in the relationship between 
OSA and other conditions24. OSA was also reported to be associated with liver and visceral fat accumulation25,26, 
although the associations were much weaker than those between BMI and adiposity. Similarly, our results indi-
cated that the relationship between OSA and adipose accumulation in skeletal muscles might be largely mediated 
by obesity.
Interestingly, some associations of OSA with skeletal muscle indices were different between men and women. 
For women, age and obesity (BMI and body fat indices) could account for all of these associations, while the AHI 
was independently associated with skeletal muscle mass only in men. Associations of OSA with BMI and adipos-
ity were reported to differ between men and women. Women with OSA had a higher BMI than men with OSA 
of the same severity, suggesting that the impact of obesity could be greater in women27. The association of OSA 
with abdominal fat accumulation was stronger in men than in women, while obesity had a stronger association 
with abdominal fat in women26,28. These previous findings may be consistent with our results on skeletal muscle 
because obesity, rather than OSA, had a stronger link with adiposity in women than in men, although the mech-
anisms of sex differences relevant to OSA have not been elucidated.
Several limitations of this study should be mentioned. First, this was a cross-sectional study of an Asian pop-
ulation. Thus, because of its cross-sectional design our study could not reveal the causative relationship between 
skeletal muscle changes and OSA. In addition, we did not have CT measurements after continuous positive airway 
pressure (CPAP) therapy. A prospective longitudinal study of patients on CPAP therapy may clarify the impact 
of OSA on skeletal mass. Also, anthropometric values differ among ethnic groups13,29. Ethnic cohorts other than 
Asians should be studied. Second, skeletal muscles were assessed only in the lumbar region. A significant cor-
relation between lumbar muscle mass measured by CT and MRI and total skeletal muscle volume assessed by 
dual-energy X-ray absorptiometry and MRI was reported15,30. Several studies evaluated skeletal muscles using CT 
images at the lumbar level as a surrogate marker for total skeletal muscle volume7,16,18,31,32. In addition, we showed 
a strong correlation between CT-measured skeletal muscle mass at the third lumbar vertebra and bioelectrical 
impedance analysis (BIA)-measured skeletal muscle mass of the whole body (Supplementary Figure S1). On the 
other hand, upper airway dilator muscle dysfunction has a specific role in the pathogenesis of OSA33. Hypoglossal 
nerve stimulation to dilator muscles has been proposed as a novel therapeutic option for OSA34. Thus, upper res-
piratory muscle changes may have different associations with OSA from other skeletal muscle changes, although 
we do not have data on upper airway muscles for analysis. The relationships between upper respiratory muscle 
changes and OSA should be addressed in future studies. Third, physical activity was assessed by questionnaires in 
this study, the results of which might be different from those obtained by objective measurements.
In conclusion, the severity of OSA did not correlate with skeletal muscle depletion. Conversely, patients with 
more severe OSA had a larger mass of skeletal muscles than those with less severe OSA even after adjustment 
for the strong effect of obesity, although this association was weak and limited to men. The severity of OSA was 
associated with low SMD, suggesting fat infiltration into skeletal muscles; however, this relationship was not inde-
pendent from obesity. To clarify the roles of skeletal muscles in the pathogenesis of OSA and its consequences, 
these limited associations between OSA and skeletal muscle indices should be re-examined in future studies of 
other cohorts.
β P value R2 β P value R2
Model 1 Men (n = 239) Women (n = 95)
AHI (events/h) — 0.939 — 0.823
Age (years) −0.55 <0.001 0.235 −0.45 <0.001 0.086
BMI (kg/m2) −0.42 <0.001 0.116 −0.64 <0.001 0.290
Cumulative R2 0.351 0.376
Model 2
AHI (events/h) — 0.839 — 0.788
Age (years) −0.49 <0.001 0.211 −0.36 <0.001 0.069
Visceral fat area index (cm2/m2) −0.26 <0.001 0.093 −0.27 0.026 0.131
Subcutaneous fat area index (cm2/m2) −0.20 0.002 0.036 −0.38 0.007 0.162
Cumulative R2 0.340 0.362
Table 4. Multivariate regression analysis predicting skeletal muscle density in men and women. Abbreviations: 
BMI, body mass index; AHI, apnea-hypopnea index; β, standardized regression coefficient; R2, coefficient of 
determination.
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Methods
Patients. We retrospectively examined data on consecutive patients who underwent diagnostic full overnight 
PSG at the Sleep Unit of Kyoto University Hospital between January 2010 and December 2012. All had been 
referred to our sleep unit under suspicion of OSA with symptoms such as daytime sleepiness or habitual snoring. 
Inclusion criteria were age between 40 and 85 years, and no prior diagnosis of or treatment for OSA. Exclusion 
criteria were as follows: no CT scan, sleep disordered breathing other than OSA, steroid use, systemic inflamma-
tory disease (i.e., connective tissue diseases), and malignancy. The Kyoto University Graduate School and Faculty 
of Medicine Ethics Committee approved this study (R0480) and waived the requirement for written informed 
consent from participants due to the study’s retrospective nature. All the performances were in accordance to the 
Declaration of Helsinki. Patient information was anonymized and de-identified prior to analysis.
Polysomnography. The diagnosis of OSA was confirmed by overnight PSG (SomnoStar pro, Cardinal 
Health, Dublin, OH, USA or Alice 4, Philips Respironics, Inc., Murrysville, PA, USA) as previously described35. 
Apnea was defined as the continuous cessation of airflow for at least 10 s and hypopnea was defined as a reduction 
in airflow by nasal pressure ≥50% lasting at least 10 s accompanied by a decrease in SpO2 ≥3% and/or associated 
with arousal. Apnea-hypopnea index (AHI) values were calculated as the number of episodes of apnea and hypo-
pnea per h over total sleep time.
Physical activity. We assessed self-reported physical activity with questionnaires on frequency and time 
spent on three levels of physical activity. Three levels were vigorous (jogging, swimming, strenuous sports, bicy-
cling on hills), moderate (housework, ballroom dancing, golf, bicycling on level ground, regular walking), and 
light (office work, strolling, personal care)36. Average intensity of activity was defined using metabolic equivalents 
(MET, kcal·kg−1·body weight·h−1) as follows: 9 METs for vigorous, 6 for moderate, and 3 for light37. The amount 
of physical activity (kcal/w) was calculated by multiplying the corresponding MET values by time spent and body 
weight, and summing up the values. The summed physical activity values were defined as the physical activity 
index. Also, the maximum intensity of physical activity (vigorous, moderate, light, or no activity) was used as the 
parameter of physical activity.
Measurement of skeletal muscle and visceral and subcutaneous adipose tissue. Patients who 
agreed to our recommendation underwent an abdominal CT within 30 days of the diagnostic PSG before start-
ing CPAP therapy. Unenhanced transverse CT was performed with an Aquilion 64 CT system (Toshiba Medical 
Systems Corporation, Tochigi, Japan). In this study, CT images of 7 mm slices were used for the analysis of skeletal 
muscle area and muscle density.
For skeletal muscle, two consecutive transverse CT images extending from the third lumbar vertebrae in the 
inferior direction were assessed, then averaged. Skeletal muscle tissues quantified included the psoas, erector spi-
nae, quadratus lumborum, transversus abdominus, internal and external obliques, and rectus abdominus. Images 
were analyzed with a workstation (AZE VirtualPlace 99, AZE of America, Ltd., Irvine, CA, USA). Skeletal muscle 
was identified and quantified by Hounsfield Unit thresholds of −29 to +150. Cross-sectional area for muscle 
was normalized for height in meters squared (cm2/m2) and described as the SMI4,7,15,16,18,19,31,32. SMD, which was 
studied as a correlate of muscle density determined by CT38, was reported for the entire muscle area at the third 
lumbar vertebra7,18. The intraclass correlation coefficients for the SMI and SMD from 50 random subset samples 
were both >0.95.
The lumbar skeletal muscle area was shown to be strongly correlated with the whole skeletal muscle mass15,30. 
To determine whether SMI at the third lumbar vertebra is valid as a surrogate index for total skeletal muscle vol-
ume, we investigated the association between SMI and the whole body skeletal muscle mass obtained from BIA in 
another cohort of OSA patients (n = 68). For BIA, patients were assessed in the supine position by a body compo-
sition analyzer (InBody S20; Biospace, Seoul, Korea). Appendicular skeletal muscle mass (ASM) normalized for 
height in meters squared was used as an indicator of total skeletal muscle volume39. SMI was strongly correlated 
with ASM/height2 (r = 0.804, P < 0.001, Supplementary Figure S1).
For the VFA and SFA, CT images at the level of the umbilicus were assessed40. VFA and SFA were quantified 
with the same workstation mentioned above and as previously described26. VFA and SFA were both normalized 
for height in meters squared (cm2/m2) and described as the VFA index and SFA index, respectively.
Statistical analysis. To evaluate the clinical features of each sex, we classified the participants into men 
and women. All values were expressed as means ± standard deviations, percentages, or medians [interquar-
tile range] unless stated otherwise. Continuous variables were compared using an unpaired Student’s t test or 
Mann-Whitney U test, as appropriate. Categorical variables were compared using a chi-squared test or Fisher’s 
exact test, as appropriate. To analyze the correlation between the severity of OSA and the SMI or SMD, Pearson 
or Spearman rank correlation coefficients were calculated for each sex, as appropriate. To test our hypothesis 
that SMI and SMD were associated with the severity of OSA, we performed a multivariate regression analysis for 
each sex. As covariates for SMI, we included age, BMI, and the physical activity index, which were shown to be 
associated with muscle mass4,7,15,16,19,32,41, and the VFA index, SFA index, and AHI, the latter of which is usually 
taken as a parameter of OSA severity. As covariates for SMD, we included age, BMI, VFA index, and SFA index, 
which were associated with muscle density7,17,18,38, and AHI. When multiple independent variables had strong 
collinearity (r >0.70), one was selected. In the sample size calculation, when the effect size was 0.15, the statistical 
power level was 0.8, the number of predictors was 4, and the probability level was 0.05, the minimum required 
sample size for multiple regression analysis was 84. During 2010–2012, the number of eligible female patients 
was 95 and that of male patients was 239. Thus, we decided to include all consecutive patients during this period. 
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Two-tailed P value < 0.05 was deemed statistically significant. All statistical analyses were performed using JMP 
11.2.0 software (SAS Institute Inc., Cary, NC, USA).
Data availability. The datasets analyzed during the current study are available from the corresponding 
author on reasonable request.
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